NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
72.92 -1.30 (-1.75%) GOLD FUTURES
2,346.40 -22.90 (-0.97%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,130.55 +1,054.00 (+1.95%)
REGN Jun 2024 1180.000 call
| Previous close | 2.1500 |
| Open | 3.4500 |
| Bid | 0.0000 |
| Ask | 4.5000 |
| Strike | 1,180.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.7000 - 3.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
ZacksHealth Care Stocks Show Relative Strength as S&P 500 Stalls
Several stocks are breaking out and trading near all-time highs.
Insider MonkeyIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy sector. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
BenzingaFDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
